MeiraGTx(MGTX)
NEW YORK, NYBiotechnology
Focus: MeiraGTx is a publicly-traded gene therapy company focused on rare genetic diseases, particularly in ophthalmology, neurology, and radiation-induced disorders. The company operates at early-to-mid clinical stage with a lean portfolio of Phase 1/2 programs and no marketed products.
Profile data last refreshed 5h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
6-2 this month
Stable — net -2 jobs in 30d
3 added, 5 removed. Backfill posture.
Should You Work at MeiraGTx?
AI assessmentMeiraGTx offers meaningful gene therapy specialization and recent financial stabilization, but early-stage clinical risk, persistent losses, and sparse hiring signal a high-stakes bet on unproven candidates rather than a stable growth opportunity.
Why Work Here
- Access to cutting-edge AAV gene therapy platform across multiple rare disease indications with unmet medical need
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
16 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$33M
Pipeline & Clinical Trials
Prior exposure to AAV-CNGA3 or AAV-CNGB3
AchromatopsiaClinical Trials (1)
NCT03278873Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
N/AHelp build intelligence for MeiraGTx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.